Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Michel Delforge,Nina Shah,Paula Rodríguez-Otero,Julia Braverman,Devender Dhanda,Ling Shi,Shien Guo,Peiwen Yu,Weiqin Liao,Timothy B Campbell,Nikhil C Munshi

doi:10.1182/blood-2021-145155

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Michel Delforge, Nina Shah + Show 9 more

Open Access

https://doi.org/10.1182/blood-2021-145155

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2021
Citations: 5

Affiliation: Bristol-Myers Squibb (United States), University of California, San Francisco, Dana-Farber Cancer Institute, Ithaka Harbors, Clinica Universidad de Navarra

#Relapsed And Refractory Multiple Myeloma #Meaningful Improvement In Fatigue + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)

Full Text